Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance] (Enbrel-JIA)

Pfizer

Status: Completed

Conditions: Juvenile Idiopathic Arthritis

Treatments: Drug: Etanercept (genetical recombination)

Study type: Observational

Funder types: Industry

Identifiers

NCT01145352

B1801130

0881Y1-4689

Details and patient eligibility

About

This surveillance is conducted to survey the followings under the post marketed drug utilization on the patients who are administrated ENBREL as a treatment for active polyarticular JIA.

1. Primary Occurrence status of Adverse Events; incidence of all adverse events, serious adverse events
2. Secondary Factors affecting safety and to confirm the efficacy such as DAS28.

Full description

All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis during registered period (2.5 year).

Enrollment: 113 patients

Sex: All

Ages: 5 to 16 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients in active polyarticular JIA (restricted to the case of lack of effect by other treatment) during enrollment period (2.5years).
• Patients receiving Enbrel for JIA as diagnosed by a qualified physician.
• Age 5 - 16 years

Exclusion criteria

• Patients not administered ENBREL

Trial design

113 participants in 1 patient group

Etanercept (genetical recombination)

Description:

All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis during registered period (2.5 year).

Treatment:

Drug: Etanercept (genetical recombination)